Perkins D, Wang Z, Donovan C, et al. Regulation of CTLA-4 expression during T cell activation. J Immunol.
1996;156(11):4154-4159.
Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint
regulators. Front Immunol. 2015. doi:10.3389/fimmu.2015.00418.
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol.
2013;13(4):227-242.
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;
271(5256):1734-1736.
Linsley PS, Brady W, Grasmere L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen
B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med.
1991;173(3):721-730.
Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation.
Immunity. 1994;1(5):405-413.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive
lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role
of CTLA-4. Immunity. 1995;3(5):541-547.
Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their
inhibition. Am J Clin Oncol. 2016;39(1):98-106.
Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science.
2008;322(5899):271-275.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-264.
Melero I, Berman DM, Aznar MA, Koran AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of
targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457-472.
Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T
cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303-309.
Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in
CTLA-4-deficient CD8+ T cells. Eur J Immunol. 1998;28(10):3137-3143.
Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature.
1994;369(6482):648-652.
Viega-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B. Response of naïve and memory CD8+ T cells to
antigen stimulation in vivo. Nat Immunol. 2000;1(1):47-53.
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human
colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964.
Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical
outcome. Nat Rev Cancer. 2012; 12(4):298-306.
Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti–CTLA-4 enhances CD8+ T-cell memory
formation, function, and maintenance. Proc Natl Acad Sci U S A. 2011;108(1):266-271.
Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells
co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J Exp Med. 2013; 210(9):1695-1710.
Amos SM, Duong CPM, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood. 2011;
118(3):499-509.
Beavis PA, Henderson MA, Giuffrida L, et al. Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor
immune responses through CD4Foxp3 cell-mediated modulation of CD103 dendritic cells. Cancer Immunol Res.
2018;6(9):1069-1081.
Saito T, Nishikawa H, Wada H, et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis
of colorectal cancers. Nat Med. 2016;22(6):679-684.
Tao H, Mimura Y, Aoe K, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells
combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012;75(1):95-101.
Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic
antibodies. Expert Opin Biol Ther. 2006;6(11):1161-1173.
Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor
activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32-42.
Chen I-J, Chuang C-H, Hsieh Y-C, et al. Selective antibody activation through protease-activated
pro-antibodies that mask binding sites with inhibitory domains. Sci Rep. 2017;7(1):11587.
doi:o10.1038/s41598-017-11886-7.
Tuve S, Chen B-M, Liu Y, et al. Combination of tumor site–located CTL-associated antigen-4 blockade and
systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res.
2007;67(12):5929-5939.
Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJM. Controlled local delivery of CTLA-4 blocking
antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin
Cancer Res. 2013;19(19):5381-5389.